Logo Logo
Help
Contact
Switch Language to German
Tillack, Cornelia; Ehmann, Laura Maximiliane; Friedrich, Matthias; Laubender, Ruediger P.; Papay, Pavol; Vogelsang, Harald; Stallhofer, Johannes; Beigel, Florian; Bedynek, Andrea; Wetzke, Martin; Maier, Harald; Koburger, Maria; Wagner, Johanna; Glas, Jürgen; Diegelmann, Julia; Koglin, Sarah; Dombrowski, Yvonne; Schauber, Jürgen; Wollenberg, Andreas; Brand, Stephan (2014): Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-gamma-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment. In: Gut, Vol. 63, No. 4: pp. 567-577
[img]
Preview
1MB

Abstract

Background We analysed incidence, predictors, histological features and specific treatment options of anti-tumour necrosis factor alpha (TNF-alpha) antibody-induced psoriasiform skin lesions in patients with inflammatory bowel diseases (IBD). Design Patients with IBD were prospectively screened for anti-TNF-induced psoriasiform skin lesions. Patients were genotyped for IL23R and IL12B variants. Skin lesions were examined for infiltrating Th1 and Th17 cells. Patients with severe lesions were treated with the anti-interleukin (IL)-12/IL-23 p40 antibody ustekinumab. Results Among 434 anti-TNF-treated patients with IBD, 21 (4.8%) developed psoriasiform skin lesions. Multiple logistic regression